European Commission authorises Pfizer-BioNTech XFG-adapted COVID-19 vaccine for the 2026–2027 vaccination season
- nuaxia
- 8月4日
- 讀畢需時 2 分鐘
The updated vaccine is authorised for individuals aged six months and older and aligns the EU COVID-19 vaccination programme with the currently circulating XFG variant.
The European Commission has authorised the Pfizer-BioNTech XFG-adapted COVID-19 vaccine for active immunisation against COVID-19 in individuals aged six months and older across the European Union, Iceland, Liechtenstein and Norway, following a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP).
The approval updates the vaccine composition for the 2026–2027 respiratory season, supporting continued protection against the currently circulating XFG variant while maintaining the established mRNA vaccine platform.
Field | Content |
Alert Type | Drug Approval |
Drug Name | Pfizer-BioNTech XFG-adapted COVID-19 vaccine (COMIRNATY®, COVID-19 Vaccine, mRNA) |
Indication | Active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals aged six months and older. (Pfizer) |
Therapy Area(s) | Infectious Diseases; Vaccines |
Geography | European Union (European Commission) |
What Happened | On 29 July 2026, the European Commission granted marketing authorisation for the Pfizer-BioNTech XFG-adapted COVID-19 vaccine for the 2026–2027 vaccination season. The updated formulation targets the XFG variant of the JN.1 lineage following the EMA Emergency Task Force recommendation and is authorised for active immunisation in individuals aged six months and older throughout all EU Member States, as well as Iceland, Liechtenstein and Norway. This updates the existing marketing authorisation with a revised seasonal vaccine formulation rather than representing a first approval. (Pfizer) |
Why It Matters | The authorisation ensures healthcare providers have an updated COVID-19 vaccine aligned with the variants expected to circulate during the 2026–2027 respiratory season. Updating vaccine composition in response to viral evolution is intended to maintain vaccine relevance, although uptake and public health impact will depend on national vaccination programmes and recommendations. (Pfizer) |
Supporting Context | The approval follows the CHMP's positive opinion issued on 23 July 2026 and the EMA Emergency Task Force recommendation to target the XFG variant after reviewing available epidemiological and immunogenicity data. Pfizer and BioNTech stated that manufacturing had already begun to support vaccine availability ahead of the respiratory virus season. (Pfizer) |
Key Takeaway | The European Commission has authorised an updated Pfizer-BioNTech COVID-19 vaccine targeting the XFG variant, enabling deployment of the 2026–2027 seasonal formulation across the EU. (Pfizer) |
What to Watch | National vaccination recommendations, country-level procurement and rollout schedules, and regulatory decisions in other jurisdictions will determine when the updated vaccine becomes available to eligible populations. (Pfizer) |
Primary Source | |
Relevant Date | 29 July 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
留言